Cue Biopharma Competitors and Similar CompaniesClear all
Cue Biopharma's competitors and similar companies include Sorrento Therapeutics, Momenta Pharmaceuticals and Alnylam.
 Cue Biopharma Cue Biopharma is an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cells for the treatment of cancer and autoimmune disease. |  Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
|  Momenta Pharmaceuticals Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules. |  Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. | |
Founding Date | Founding Date 2015 | Founding Date 2006 | Founding Date 2001 | Founding Date 2002 |
Type | Type Public | Type Public | Type Subsidiary | Type Public |
Tags | ||||
Locations | Locations Cambridge, US HQ | Locations San Diego, US HQ San Diego, US | Locations Cambridge, US HQ Dublin, IE Cambridge, US | |
Employees | Employees 4664% increase | Employees 31019% decrease | Employees 76 | Employees 1,32324% increase |
Valuation ($) | Valuation ($) 107.3 m | Valuation ($) 1.5 m | Valuation ($) N/A | Valuation ($) 36.5 b |
Financial | ||||
Revenue (est.) | Revenue (est.) $27.5m (FY, 2025) | Revenue (est.) $62.8m (FY, 2022) | Revenue (est.) $23.9m (FY, 2019) | Revenue (est.) $3.7b (FY, 2025) |
Net income | Net income ($26.6m) (FY, 2025) | Net income ($577.8m) (FY, 2022) | Net income ($290.1m) (FY, 2019) | Net income $313.7m (FY, 2025) |
Funding | ||||
Total funding raised | Total funding raised N/A | Total funding raised $ 42.6m | Total funding raised N/A | Total funding raised $ 1.5b |
For sources of this data, please see the company profile
View Company Profiles
Sorrento Therapeutics
HQ
San Diego, US
Employees
310↓ 19% decrease
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
View companyMomenta Pharmaceuticals
HQ
Cambridge, US
Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules.
View companyAlnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View company